- Report
- October 2024
- 180 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- July 2024
- 150 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- March 2025
- 178 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 192 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- May 2024
- 131 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- February 2022
- 32 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2024
- 85 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 96 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 114 Pages
Global
From €3500EUR$3,929USD£3,035GBP
Desmopressin is a synthetic analogue of the natural hormone arginine vasopressin, used to treat endocrine and metabolic disorders. It is used to treat diabetes insipidus, a condition in which the body does not produce enough antidiuretic hormone, resulting in excessive urination and dehydration. It is also used to treat nocturnal enuresis, or bedwetting, in children. Desmopressin is available in tablet, intranasal spray, and injection forms.
Desmopressin is also used to treat von Willebrand disease, a bleeding disorder caused by a deficiency of von Willebrand factor. It is used to increase the level of von Willebrand factor in the blood, allowing it to clot more effectively.
Desmopressin is a widely used drug in the endocrine and metabolic disorders market. It is available from many pharmaceutical companies, including Novartis, Pfizer, and Merck. It is also available in generic forms from many generic drug manufacturers. Show Less Read more